AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20381003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge
Number of subjects: 38
Study 20381003 — intervention group
Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 38
Study 18322263 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16-24 mg/day)
Number of subjects: 2048
Study 18322263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2048
Study 15867860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPNDs)
Number of subjects: 54
Study 15867860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15867860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPNDs) and Placebo
Number of subjects: 54
Study 15519702 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa/Hib (PRP-T) booster dose
Number of subjects: 368
Study 15519702 — intervention group
Group type: COMPARATOR
Intervention: Unconjugated PRP (PRP) challenge dose plus separate DTPa vaccine
Number of subjects: 368
Study 11356400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy or other pharmacologic therapy started before discharge
Number of subjects: 0
Study 11356400 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic treatment plans for management of risk factors after hospitalization
Number of subjects: 0
Study 9244213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiplatelet therapy (aspirin plus ticlopidine)
Number of subjects: 496
Study 9244213 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulant therapy (phenprocoumon with initial overlapping heparin plus aspirin)
Number of subjects: 496
Study 8274324 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:80,000 adrenaline
Number of subjects: 43
Study 8274324 — intervention group
Group type: COMPARATOR
Intervention: 1.5% etidocaine with 1:200,000 adrenaline
Number of subjects: 43
Study 3488978 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate and sulfisoxizole
Number of subjects: 137
Study 3488978 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 137
Study 30326126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (76% Roux-en-Y gastric bypass, 17% sleeve gastrectomy, 7% adjustable gastric banding)
Number of subjects: 5301
Study 30326126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 5301
Study 25892603 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (6000 IU/day for 3 months, then 3000 IU/day for 3 months, followed by 2200 IU/day for 6 months)
Number of subjects: 87
Study 25892603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 25487763 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program
Number of subjects: 395
Study 25487763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 395
Study 23270285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (SH)
Number of subjects: 70
Study 23270285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 70
Study 23270285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% octenidine dihydrochloride (OCT)
Number of subjects: 70
Study 23270285 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (SS)
Number of subjects: 70
Study 20544405 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management intervention delivered by a nurse, six contacts over 8 weeks.
Number of subjects: 333
Study 19265635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies with second-generation antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) combined with lithium or divalproex
Number of subjects: 0
Study 19265635 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine
Number of subjects: 0
Study 19265635 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine combined with lithium or valproate
Number of subjects: 0
Study 15935266 — intervention group
Group type: EXPERIMENTAL
Intervention: APF foam
Number of subjects: 661
Study 15935266 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 661
Study 15935266 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel
Number of subjects: 661
Study 12529459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonogram
Number of subjects: 309
Study 12529459 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial renal scan
Number of subjects: 309
Study 12529459 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram
Number of subjects: 309
Study 12529459 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated renal scans
Number of subjects: 309
Study 10730801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active educational intervention focused on breast cancer early detection
Number of subjects: 8
Study 10730801 — intervention group
Group type: COMPARATOR
Intervention: Passive educational intervention
Number of subjects: 8
Study 10730801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active educational intervention
Number of subjects: 8
Study 9273231 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunum and large intestine
Number of subjects: 3
Study 9273231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileum and caecum
Number of subjects: 3
Study 9273231 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 3
Study 1293272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra amniotic thyroxine
Number of subjects: 82
Study 1293272 — intervention group
Group type: COMPARATOR
Intervention: Intra muscular Dexamethasone
Number of subjects: 82
Study 3883938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy alone (n = 18)
Number of subjects: 33
Study 3883938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus amitriptyline hydrochloride (n = 15)
Number of subjects: 33
Study 3883938 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment at one-year follow-up
Number of subjects: 33
Study 30953605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), 3 sessions per week
Number of subjects: 129
Study 30953605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), adjusted for infant birth weight
Number of subjects: 129
Study 30953605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), for women with previous births
Number of subjects: 129
Study 30953605 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine prenatal care only)
Number of subjects: 129
Study 29273308 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with carboplatin and paclitaxel (CT) followed by interval cytoreductive surgery and then 3 additional cycles of CT
Number of subjects: 0
Study 29273308 — intervention group
Group type: COMPARATOR
Intervention: Primary cytoreductive surgery (PCS) followed by 6 cycles of CT
Number of subjects: 0
Study 27447802 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisolone
Number of subjects: 186
Study 27447802 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg submucosal injection of prednisolone
Number of subjects: 186
Study 27447802 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (control group)
Number of subjects: 186
Study 24966145 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial reanimation surgery
Number of subjects: 86
Study 24966145 — intervention group
Group type: COMPARATOR
Intervention: Paralyzed faces
Number of subjects: 86
Study 24966145 — intervention group
Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 86
Study 22494856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil/salicylic acid (5-FU/SA)
Number of subjects: 175
Study 22494856 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 175
Study 22494856 — intervention group
Group type: COMPARATOR
Intervention: 3% diclofenac/hyaluronic acid (HA)
Number of subjects: 175
Study 20236216 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in MB-stent group
Number of subjects: 100
Study 17916949 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite 0.2 mg kg‐1 day‐1 for 30 days in addition to standard chemotherapy
Number of subjects: 50
Study 17916949 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 50
Study 15613422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/d)
Number of subjects: 199
Study 15613422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 199
Study 15613422 — intervention group
Group type: COMPARATOR
Intervention: Wheat germ placebo
Number of subjects: 199
Study 11797655 — intervention group
Group type: COMPARATOR
Intervention: Bed Rest
Number of subjects: 250
Study 11797655 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 250
Study 11797655 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ADLs (Control)
Number of subjects: 250
Study 10404946 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 33
Study 10404946 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 33
Study 10404946 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (in hot water)
Number of subjects: 33
Study 10404946 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (regular consumption)
Number of subjects: 33
Study 10404946 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (regular consumption)
Number of subjects: 33
Study 7770605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (ten times the recommended daily dose of nine vitamins)
Number of subjects: 127
Study 7770605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 2139769 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg/day during the luteal phase
Number of subjects: 26
Study 2139769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2139769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 111085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavis
Number of subjects: 30
Study 111085 — intervention group
Group type: COMPARATOR
Intervention: Alcohol abstinence alone (Control)
Number of subjects: 30
Study 30859640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at a higher platelet count threshold (< 50 x 10^9/L)
Number of subjects: 0
Study 30859640 — intervention group
Group type: COMPARATOR
Intervention: Transfusion only when platelet count drops below 25 x 10^9/L
Number of subjects: 0
Study 28472315 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysRx (physiologically individualized care)
Number of subjects: 105
Study 28472315 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 105
Study 25091846 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative quality of life score <50
Number of subjects: 431
Study 25091846 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complications (yes/no)
Number of subjects: 431
Study 25091846 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complications
Number of subjects: 431
Study 24028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 500
Study 24028414 — intervention group
Group type: COMPARATOR
Intervention: Partial or Unicompartmental Knee Replacement (UKR)
Number of subjects: 500
Study 24028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 500
Study 24028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 500
Study 24028414 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications data
Number of subjects: 500
Study 21835378 — intervention group
Group type: EXPERIMENTAL
Intervention: OU‐CMR (stress cardiac magnetic resonance observation unit testing)
Number of subjects: 109
Study 21835378 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 109
Study 21835378 — intervention group
Group type: EXPERIMENTAL
Intervention: OU‐CMR
Number of subjects: 109
Study 19608828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretch position
Number of subjects: 0
Study 19608828 — intervention group
Group type: COMPARATOR
Intervention: Traditional sitting position
Number of subjects: 0
Study 17355546 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0
Study 17355546 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine 2 mg plus caffeine 200 mg
Number of subjects: 0
Study 14731312 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16
Study 14731312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11505964 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste (0.3% triclosan and 2% copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 3392
Study 11505964 — intervention group
Group type: COMPARATOR
Intervention: Crest Cavity Fighting Toothpaste with Fluoristat (0.243% sodium fluoride in a silica base)
Number of subjects: 3392
Study 11764125 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal vertical slot resin‐based composite (RBC) restorations
Number of subjects: 90
Study 11764125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inserts with low‐viscosity resin
Number of subjects: 90
Study 11764125 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC with low‐viscosity resin liner
Number of subjects: 90
Study 8572352 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 423
Study 8572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 423
Study 8572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 423
Study 1365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (N)
Number of subjects: 96
Study 1365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard piroxicam (P)
Number of subjects: 96
Study 1365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin S.R. (I)
Number of subjects: 96
Study 1365474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac S.R. (D)
Number of subjects: 96
Study 6962709 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (160-320 mg/day)
Number of subjects: 28
Study 6962709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (oxprenolol and chlorthalidone, and hydrallazine)
Number of subjects: 28
Study 6962709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30477309 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS‐FLU 93 µg, 186 µg, or 372 µg
Number of subjects: 323
Study 30477309 — intervention group
Group type: COMPARATOR
Intervention: EDS‐placebo
Number of subjects: 323
Study 29450524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement tool kit (n=11,308 participants)
Number of subjects: 21374
Study 29450524 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group; n=10,066 participants)
Number of subjects: 21374
Study 29450524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement tool kit
Number of subjects: 21374
Study 29450524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21374
Study 26194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) laparoscopy
Number of subjects: 20
Study 26194251 — intervention group
Group type: COMPARATOR
Intervention: White-light laparoscopy
Number of subjects: 20
Study 24323628 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire intervention including free text fields for goal formulation
Number of subjects: 2782
Study 24323628 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire intervention
Number of subjects: 2782
Study 22837094 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg V710 (with or without adjuvant)
Number of subjects: 206
Study 22837094 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg V710 (with adjuvant)
Number of subjects: 206
Study 22837094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 19639497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with PCOS
Number of subjects: 38
Study 19639497 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 17667497 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LAP)
Number of subjects: 110
Study 17667497 — intervention group
Group type: COMPARATOR
Intervention: Conventional (open) Nissen fundoplication
Number of subjects: 110
Study 16254902 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training program (3 sessions/week for 14 weeks, intensity from 50% to 80% of 1RM)
Number of subjects: 20
Study 16254902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 12047481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor EL (up to 5000 mg)
Number of subjects: 8
Study 12047481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10433447 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol orally on admission and a further 300 mg for another 5 days
Number of subjects: 98
Study 10433447 — intervention group
Group type: COMPARATOR
Intervention: Standard management for thumb replantation
Number of subjects: 98
Study 8549148 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsam of Peru and spices (active substances)
Number of subjects: 29
Study 8549148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1703602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim (1 mg) single dose
Number of subjects: 18
Study 1703602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim (1 mg) multiple doses
Number of subjects: 18
Study 1703602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim (1 mg) added to atenolol
Number of subjects: 18
Study 1703602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1703602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim (1 mg)
Number of subjects: 18
Study 30898471 — intervention group
Group type: EXPERIMENTAL
Intervention: Single strain (Lactobacillus acidophilus boucardii)
Number of subjects: 90
Study 30898471 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Number of subjects: 90
Study 30200893 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 618
Study 30200893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 618
Study 30200893 — intervention group
Group type: COMPARATOR
Intervention: Both MCT and HIIT
Number of subjects: 618
Study 30200893 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 618
Study 26261902 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deficiency (fasting C–peptide ≤ 0.15 nmol/l)
Number of subjects: 430
Study 26261902 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD antibodies
Number of subjects: 430
Study 26261902 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IAA or baseline insulin use
Number of subjects: 430
Study 26261902 — intervention group
Group type: EXPERIMENTAL
Intervention: IA2 antibodies
Number of subjects: 430
Study 26261902 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnT8 antibodies
Number of subjects: 430
Study 24568798 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes-closed training program
Number of subjects: 18
Study 24568798 — intervention group
Group type: COMPARATOR
Intervention: Eyes open control group
Number of subjects: 18
Study 23451443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 200
Study 23451443 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 200
Study 20437580 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell depletion with rituximab
Number of subjects: 0
Study 17418384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray, 110 microg once daily
Number of subjects: 299
Study 16360055 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ICD upgrade
Number of subjects: 18
Study 12003381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue injection
Number of subjects: 37
Study 12003381 — intervention group
Group type: COMPARATOR
Intervention: Alcohol injection
Number of subjects: 37
Study 9856136 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfates 4&6 (CS 4&6) at a dose of 800 mg/d
Number of subjects: 104
Study 9856136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8544412 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte oxalate flux rate in stone formers
Number of subjects: 20
Study 8544412 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal fractional clearance of oxalate in stone formers
Number of subjects: 20
Study 8544412 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between erythrocyte oxalate flux rate and renal fractional clearance of oxalate
Number of subjects: 20
Study 8544412 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte oxalate flux rate in controls
Number of subjects: 20
Study 8544412 — intervention group
Group type: COMPARATOR
Intervention: Renal fractional clearance of oxalate in controls
Number of subjects: 20
Study 2216496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 30
Study 2216496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 420136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 244
Study 420136 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented)
Number of subjects: 244
Study 31045465 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids 4 g/day
Number of subjects: 100